Jefferies Cuts Price Target on Kadmon (KDMN) to $10 Following 3Q

November 10, 2016 10:35 AM EST
Get Alerts KDMN Hot Sheet
Price: $5.15 -1.53%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade KDMN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies maintained a Buy rating on Kadmon Holdings (NYSE: KDMN), and cut the price target to $10.00 (from $12.00), following the company's 3Q earnings report. KDMN reported Q3 revenues of $5.7M compared to JEF estimates of 3.8M & EPS of ($4.23) vs. estimates of ($0.90). KDMN is expected to present on 13 patients treated with tesevatinib at IASCL, taking place from Dec 4-7th.

Analyst Biren Amin commented, "KDMN release 3Q16 financial data and provided a pipeline update. The company is on track to present data for tesevatinib in NSCLC with CNS involvement this Dec 2016 at IASCL, with add'l topline data in 1Q17. For KD025, the company expects to complete enrollment in psoriasis in 1H17, and expects data in IFP and cGVHD in mid-2017. Lastly, for KD034 KDMN guided to an aNDA submission in December for two trientine formulations."

For an analyst ratings summary and ratings history on Kadmon Holdings click here. For more ratings news on Kadmon Holdings click here.

Shares of Kadmon Holdings closed at $5.48 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment